Literature DB >> 17155969

Toxicity following high-dose salvage radiotherapy after radical prostatectomy.

Charlie Jung1, Michael S Cookson, Sam S Chang, Joseph A Smith, Mary S Dietrich, Ming Teng.   

Abstract

OBJECTIVE: To assess gastrointestinal (GI) and genitourinary (GU) toxicity in patients treated with salvage radiotherapy (SRT) at doses of 70.2 Gy after radical retropubic prostatectomy (RRP). PATIENTS AND METHODS: Medical records were reviewed retrospectively to identify patients treated with SRT after RRP between January 1999 and December 2005. Of the 62 patients identified, 30 were included for analysis. GI and GU toxicity was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events and the American Urological Association Symptom Index (AUASI), respectively.
RESULTS: The median AUASI score of the 17 patients with scores before SRT was 4, of the 24 with scores after SRT was 6, and of the 15 with scores before and after SRT the median increase was 3. Of the 29 patients with GI toxicity data, nine (31%) had diarrhoea after SRT (three after <70.2 Gy and six after 70.2 Gy). In all cases, the diarrhoea was mild (grade 1). Of all patients, 12 (41%) had proctitis after SRT (four after <70.2 Gy and eight after 70.2 Gy); the proctitis was grade 1 in four and grade 2 in eight, with no cases of grade 3 proctitis. There was no statistically significant difference in the median change in AUASI scores and GI toxicity incidence between patients receiving <70.2 or 70.2 Gy of SRT.
CONCLUSION: High-dose SRT (70.2 Gy) is generally well tolerated with acceptable low-grade GI toxicity and minimal changes in AUASI scores.

Entities:  

Mesh:

Year:  2006        PMID: 17155969     DOI: 10.1111/j.1464-410X.2006.06661.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1. 

Authors:  Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-06       Impact factor: 1.862

2.  CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.

Authors:  B Detti; P Bonomo; L Masi; R Doro; S Cipressi; C Iermano; I Bonucci; D Franceschini; L Di Brina; M Baki; G Simontacchi; I Meattini; M Carini; S Serni; G Nicita; L Livi
Journal:  World J Urol       Date:  2015-06-11       Impact factor: 4.226

3.  Lower Bladder Toxicity of Salvage Versus Adjuvant Modern Radiotherapy for Prostate Cancer Patients.

Authors:  Annamaria Vinciguerra; Antonietta Augurio; Consuelo Rosa; David Fasciolo; Marzia Borgia; Valentina Milone; Michele Marchioni; Marta DI Nicola; Domenico Genovesi; Luciana Caravatta
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

4.  A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer.

Authors:  Edouard J Trabulsi; Richard K Valicenti; Alexandra L Hanlon; Thomas M Pisansky; Howard M Sandler; Deborah A Kuban; Charles N Catton; Jeff M Michalski; Michael J Zelefsky; Patrick A Kupelian; Daniel W Lin; Mitchell S Anscher; Kevin M Slawin; Claus G Roehrborn; Jeffrey D Forman; Stanley L Liauw; Larry L Kestin; Theodore L DeWeese; Peter T Scardino; Andrew J Stephenson; Alan Pollack
Journal:  Urology       Date:  2008-07-30       Impact factor: 2.649

5.  Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307 patients with prostate cancer.

Authors:  Beatrice Detti; Silvia Scoccianti; Sara Cassani; Samantha Cipressi; Donata Villari; Alberto Lapini; Calogero Saieva; Tommaso Cai; Maurizio Pertici; Irene Giacomelli; Lorenzo Livi; Marco Ceroti; Giulio Nicita; Marco Carini; Giampaolo Biti
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-18       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.